SE0300034L - Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer - Google Patents

Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer

Info

Publication number: SE0300034L
Authority: SE; Sweden
Prior art keywords: strains; parapoxvirus ovis; antiviral; preparation; cancer drugs
Prior art date: 2000-07-11

Application number

SE0300034A

Other languages

English (en)

Swedish (sv)

Other versions

SE0300034D0 (sv

Inventor

Olaf Weber

Tobias Schlapp

Angela Siegling

Andreas Knorr

Claudia Hirth-Dietrich

Gudrun Theiss

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2003-01-10

Publication date

2003-03-03

2001-05-09 Priority claimed from DE10122451A external-priority patent/DE10122451A1/de

2003-01-10 Application filed by Bayer Ag filed Critical Bayer Ag

2003-01-10 Publication of SE0300034D0 publication Critical patent/SE0300034D0/xx

2003-03-03 Publication of SE0300034L publication Critical patent/SE0300034L/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Surgery (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE0300034A 2000-07-11 2003-01-10 Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer SE0300034L (sv)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10033582		2000-07-11
DE10122451A DE10122451A1 (de)	2000-07-11	2001-05-09	Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
PCT/EP2001/007991 WO2002004002A2 (de)	2000-07-11	2001-07-11	Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs

Publications (2)

Publication Number	Publication Date
SE0300034D0 SE0300034D0 (sv)	2003-01-10
SE0300034L true SE0300034L (sv)	2003-03-03

Family

ID=26006335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE0300034A SE0300034L (sv)	2000-07-11	2003-01-10	Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer

Country Status (36)

Country	Link
US (1)	US6685950B2 (no)
EP (1)	EP1303286B1 (no)
JP (1)	JP5037775B2 (no)
CN (1)	CN1455674B (no)
AR (1)	AR029954A1 (no)
AT (1)	ATE324115T1 (no)
AU (2)	AU7063101A (no)
BG (1)	BG107448A (no)
CA (1)	CA2415397C (no)
CY (1)	CY1105408T1 (no)
CZ (1)	CZ200371A3 (no)
DE (1)	DE50109630D1 (no)
DK (2)	DK1303286T3 (no)
EE (1)	EE200300018A (no)
ES (1)	ES2262663T3 (no)
FI (1)	FI20030037A7 (no)
GB (1)	GB2381454B8 (no)
HK (1)	HK1054329B (no)
HR (1)	HRP20030096A2 (no)
HU (1)	HUP0400479A3 (no)
IL (1)	IL153643A0 (no)
LT (1)	LT5079B (no)
LU (1)	LU90997B1 (no)
LV (1)	LV12990B (no)
MA (1)	MA26927A1 (no)
MX (1)	MXPA03000279A (no)
NO (1)	NO20030082L (no)
NZ (1)	NZ523534A (no)
PL (1)	PL366397A1 (no)
PT (1)	PT1303286E (no)
RU (1)	RU2003104525A (no)
SE (1)	SE0300034L (no)
SI (1)	SI21122A (no)
SK (1)	SK362003A3 (no)
UY (1)	UY26832A1 (no)
WO (1)	WO2002004002A2 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19922407A1 (de) *	1999-05-14	2000-11-16	Bayer Ag	Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) *	2000-11-23	2006-08-29	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
CN101676389A (zh) *	2000-11-23	2010-03-24	巴法里安诺迪克有限公司	改良安卡拉痘苗病毒变体
US7628980B2 (en) *	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en)	2001-06-13	2004-02-27	Bayer Ag	Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP1499355A4 (en) *	2001-12-07	2005-10-05	Bayer Pharmaceuticals Corp	USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
AU2003239805B2 (en) *	2002-04-19	2009-09-10	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
ES2305514T5 (es) *	2002-09-05	2019-06-14	Bavarian Nordic As	Método para la amplificación de un poxvirus en condiciones exentas de suero
CN1984666A (zh) *	2004-07-13	2007-06-20	爱库里斯股份有限两合公司	与其他抗病毒剂联合治疗hiv/aids的副痘病毒
PT1951274E (pt) *	2005-11-24	2009-12-14	Aicuris Gmbh & Co Kg	Parapoxvírus em combinação com agentes quimioterapêuticos citotóxicos clássicos como bioquimioterapia para o tratamento de cancro
JP5004990B2 (ja) *	2009-03-31	2012-08-22	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト	パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
WO2011072871A1 (en) *	2009-12-18	2011-06-23	Bavarian Nordic A/S	Production of ifn-lambda by conventional dendritic cells and uses thereof
JP5699093B2 (ja) *	2012-01-05	2015-04-08	アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓＧｍｂＨ＆Ｃｏ．ＫＧ	パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) *	2017-09-07	2019-06-01	德商艾庫瑞斯公司	使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) *	2021-11-10	2023-05-19	Aicuris Gmbh & Co. Kg	Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) *	2021-11-10	2023-05-19	Aicuris Gmbh & Co. Kg	Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2714665A1 (de) *	1977-04-01	1978-10-05	Mayr Anton	Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) *	1984-02-17	1997-11-06	Bayer Ag	Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) *	1987-08-10	1995-08-22	Duke University	Poxvirus insertion/expression vector
DE4405841C1 (de) *	1994-02-23	1995-01-05	Mayr Anton Prof Dr Med Vet Dr	Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) *	1994-11-14	1997-07-15	Tawashi; Rashad	Drug delivery of nitric oxide
JP2000507092A (ja) *	1996-02-28	2000-06-13	バイエル・アクチエンゲゼルシヤフト	外来ｄｎａを含むパラポックスウイルス、それらの製造及びワクチンにおけるそれらの使用
CN1217751A (zh) *	1996-03-29	1999-05-26	奥塔戈大学	副痘病毒载体
ATE203678T1 (de) *	1996-04-15	2001-08-15	Anton Prof Dr Med Vet Dr Mayr	Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
SE9700617D0 (sv) *	1997-02-21	1997-02-21	Kjell Alving	New composition
DE19843222A1 (de) *	1998-09-22	2000-03-30	Hassan Jomaa	Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
AU775956B2 (en) *	1998-11-02	2004-08-19	Otago Innovation Limited	Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2

2001
- 2001-07-11 EP EP01949489A patent/EP1303286B1/de not_active Expired - Lifetime
- 2001-07-11 HU HU0400479A patent/HUP0400479A3/hu unknown
- 2001-07-11 LU LU90997A patent/LU90997B1/en active
- 2001-07-11 JP JP2002508456A patent/JP5037775B2/ja not_active Expired - Lifetime
- 2001-07-11 CA CA2415397A patent/CA2415397C/en not_active Expired - Lifetime
- 2001-07-11 MX MXPA03000279A patent/MXPA03000279A/es unknown
- 2001-07-11 WO PCT/EP2001/007991 patent/WO2002004002A2/de not_active Ceased
- 2001-07-11 AR ARP010103292A patent/AR029954A1/es unknown
- 2001-07-11 PT PT01949489T patent/PT1303286E/pt unknown
- 2001-07-11 SK SK36-2003A patent/SK362003A3/sk not_active Application Discontinuation
- 2001-07-11 AU AU7063101A patent/AU7063101A/xx active Pending
- 2001-07-11 IL IL15364301A patent/IL153643A0/xx active IP Right Grant
- 2001-07-11 AT AT01949489T patent/ATE324115T1/de active
- 2001-07-11 FI FI20030037A patent/FI20030037A7/fi not_active IP Right Cessation
- 2001-07-11 HK HK03106613.1A patent/HK1054329B/zh not_active IP Right Cessation
- 2001-07-11 UY UY26832A patent/UY26832A1/es not_active Application Discontinuation
- 2001-07-11 AU AU2001270631A patent/AU2001270631B2/en not_active Expired - Fee Related
- 2001-07-11 NZ NZ523534A patent/NZ523534A/en not_active IP Right Cessation
- 2001-07-11 ES ES01949489T patent/ES2262663T3/es not_active Expired - Lifetime
- 2001-07-11 DK DK01949489T patent/DK1303286T3/da active
- 2001-07-11 HR HR20030096A patent/HRP20030096A2/xx not_active Application Discontinuation
- 2001-07-11 CZ CZ200371A patent/CZ200371A3/cs unknown
- 2001-07-11 DE DE50109630T patent/DE50109630D1/de not_active Expired - Lifetime
- 2001-07-11 SI SI200120048A patent/SI21122A/sl not_active IP Right Cessation
- 2001-07-11 EE EEP200300018A patent/EE200300018A/xx unknown
- 2001-07-11 RU RU2003104525/15A patent/RU2003104525A/ru not_active Application Discontinuation
- 2001-07-11 PL PL01366397A patent/PL366397A1/xx not_active Application Discontinuation
- 2001-07-11 GB GB0302630A patent/GB2381454B8/en not_active Expired - Fee Related
- 2001-07-11 CN CN01812685.5A patent/CN1455674B/zh not_active Expired - Lifetime
- 2001-07-11 US US09/903,013 patent/US6685950B2/en not_active Expired - Lifetime
2003
- 2003-01-08 BG BG107448A patent/BG107448A/bg unknown
- 2003-01-08 NO NO20030082A patent/NO20030082L/no unknown
- 2003-01-10 SE SE0300034A patent/SE0300034L/xx not_active Application Discontinuation
- 2003-01-10 MA MA26994A patent/MA26927A1/fr unknown
- 2003-01-10 DK DK200300015A patent/DK200300015A/da not_active Application Discontinuation
- 2003-02-03 LT LT2003009A patent/LT5079B/lt not_active IP Right Cessation
- 2003-02-11 LV LVP-03-14A patent/LV12990B/lv unknown
2006
- 2006-07-24 CY CY20061101024T patent/CY1105408T1/el unknown

Also Published As

Publication number	Publication date
JP2004517807A (ja)	2004-06-17
LV12990B (en)	2003-08-20
GB2381454A8 (en)	2007-10-23
BG107448A (bg)	2003-11-28
MA26927A1 (fr)	2004-12-20
SI21122A (sl)	2003-08-31
EP1303286B1 (de)	2006-04-26
UY26832A1 (es)	2002-01-31
JP5037775B2 (ja)	2012-10-03
FI20030037L (fi)	2003-03-10
HUP0400479A2 (hu)	2004-06-28
HK1054329A1 (en)	2003-11-28
PT1303286E (pt)	2006-08-31
HUP0400479A3 (en)	2006-02-28
US20030021769A1 (en)	2003-01-30
HRP20030096A2 (en)	2005-02-28
NZ523534A (en)	2005-02-25
EE200300018A (et)	2004-10-15
DK200300015A (da)	2003-03-07
EP1303286A2 (de)	2003-04-23
AU7063101A (en)	2002-01-21
SK362003A3 (en)	2003-07-01
GB2381454A (en)	2003-05-07
WO2002004002A3 (de)	2002-10-31
CN1455674A (zh)	2003-11-12
LT2003009A (en)	2003-08-25
DK1303286T3 (da)	2006-08-28
ATE324115T1 (de)	2006-05-15
AR029954A1 (es)	2003-07-23
HK1054329B (zh)	2005-10-07
NO20030082D0 (no)	2003-01-08
GB0302630D0 (en)	2003-03-12
CA2415397C (en)	2011-04-26
LU90997B1 (en)	2003-01-08
PL366397A1 (pl)	2005-01-24
FI20030037A7 (fi)	2003-03-10
WO2002004002A2 (de)	2002-01-17
CY1105408T1 (el)	2010-04-28
GB2381454B8 (en)	2007-10-23
NO20030082L (no)	2003-01-08
CA2415397A1 (en)	2002-01-17
MXPA03000279A (es)	2004-04-05
CN1455674B (zh)	2019-03-29
ES2262663T3 (es)	2006-12-01
RU2003104525A (ru)	2004-06-27
DE50109630D1 (de)	2006-06-01
US6685950B2 (en)	2004-02-03
IL153643A0 (en)	2003-07-06
CZ200371A3 (cs)	2003-04-16
SE0300034D0 (sv)	2003-01-10
LT5079B (lt)	2003-12-29
GB2381454B (en)	2004-11-24
AU2001270631B2 (en)	2005-07-07

Publication	Publication Date	Title
SE0300034L (sv)	2003-03-03	Användning av stammar av Parapoxvirus ovis för framställning av antivirala läkemedel och läkemedel mot cancer
TNSN07150A1 (en)	2008-11-21	Semi-soft c-class immunostimulatory oligonucleotides
BRPI0414019A (pt)	2006-10-24	nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos
WO2005042018A3 (en)	2005-07-21	C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2006072625A8 (en)	2007-03-29	Anti-kir combination treatments and methods
CY1105221T1 (el)	2010-03-03	Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
WO2005009355A3 (en)	2005-03-31	Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
EA200100954A1 (ru)	2002-04-25	Производные камптотецина, обладающие противоопухолевой активностью
MXPA05014163A (es)	2006-02-24	Metodos y dispositivos para el tratamiento de lesiones cutaneas.
EA201991174A1 (ru)	2020-01-31	Комбинация двух противовирусных препаратов для лечения гепатита c
WO2022155541A8 (en)	2023-04-20	Interferon prodrugs and methods of making and using the same
BR0209645A (pt)	2004-07-06	Oxazolo- e furopirimidinas e seu uso como medicamentos
UY28313A1 (es)	2004-12-31	Nonadepsipeptidos acilados
MXPA05009526A (es)	2005-12-15	Uso de virus de mixoma para el tratamiento terapeutico de cancer e infeccion viral cronica.
WO2004026260A3 (en)	2004-07-15	Prophylactic and therapeutic hiv aptamers
TW200621799A (en)	2006-07-01	Acylated nonadepsipeptides II
PL372769A1 (en)	2005-08-08	Cyanoguanidine prodrugs
WO2022127945A3 (es)	2022-12-22	Cigb-300 para uso en la inducción de inmunidad antitumoral y antiviral
BRPI0112407B8 (pt)	2021-05-25	uso de cepas de parapoxvírus ovis para produzir medicamentos antivirais e medicamentos contra câncer
CY1113230T1 (el)	2016-04-13	1-φαινυλ-2-ετεροαρυλ-υποκατεστημενα παραγωγα βενζιμιδαζολιου, η χρηση αυτων για την παρασκευη φαρμακων που χρησιμοποιουνται στη θεραπεια ανοσολογικων ασθενειων
WO2008087340A3 (fr)	2008-09-18	UTILISATION D' OLIGO-β-(1,3)-GLUCANES MODIFIES POUR LE TRAITEMENT DE MALADIES DU SYSTEME IMMUNITAIRE, OLIGO-β-(1,3)-GLUCANE-(1,3)- MANNOSE, OLIGO-β-(1.3)-GLUCANE-(1,3)- MANNITOL ET LEURS DERIVES, LEURS PROCEDES DE PREPARATION ET MEDICAMENTS LES CONTENANT
WO2003013593A3 (fr)	2003-10-02	Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
DE60231605D1 (de)	2009-04-30	Immunomodulator zur bekämpfung von durch humanen immunschwächevirus (hiv) vermittelte krankheiten/infektionen
MX2021015494A (es)	2022-04-18	Profarmacos de quinazolina para el tratamiento de infecciones viricas y otras enfermedades.
TH85797A (th)	2007-08-10	วิธีการของการทำให้เกิดแอนติบอดีที่ลบล้างกับไวรัสภูมิคุ้มกันบกพร่องของมนุษย์

Legal Events

Date	Code	Title	Description
2006-02-07	NAV	Patent application has lapsed